每经AI快讯,3月28日,再鼎医药在港交所公告称,2024年全年营收为3.99亿美元,上年同期为2.67亿美元;全年产品收入净额增加1.309亿美元(或49%)至3.976亿美元;全年亏损净额减少7750万美元(或23%)至2.571亿美元,主要由于产品收入增长快于净营运开支,被利息收入减少及汇兑亏损增加所抵销。(文章来源:每日经济新闻)
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.